Topics

Twelve-year follow-up after peptide receptor radionuclide therapy

20:00 EDT 29 Apr 2019 | AAAS

(Society of Nuclear Medicine and Molecular Imaging) A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life. The study is featured in the April issue of The Journal of Nuclear Medicine.

Original Article: Twelve-year follow-up after peptide receptor radionuclide therapy

NEXT ARTICLE

More From BioPortfolio on "Twelve-year follow-up after peptide receptor radionuclide therapy"

Quick Search